These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25373277)

  • 1. Ipilimumab, a human monoclonal antibody for treatment of unresectable or metastatic melanoma.
    Wilkes GM
    Oncology (Williston Park); 2011 Jul; 25(7 Suppl Nurse Ed):46-7. PubMed ID: 25373277
    [No Abstract]   [Full Text] [Related]  

  • 2. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    Hanaizi Z; van Zwieten-Boot B; Calvo G; Lopez AS; van Dartel M; Camarero J; Abadie E; Pignatti F
    Eur J Cancer; 2012 Jan; 48(2):237-42. PubMed ID: 22030452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nursing management of patients with metastatic melanoma receiving ipilimumab.
    Bryce J; Passoni C
    Oncol Nurs Forum; 2013 May; 40(3):215-8. PubMed ID: 23615135
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
    Di Giacomo AM; Margolin K
    Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ipilimumab lesson in melanoma: achieving long-term survival.
    Delyon J; Maio M; Lebbé C
    Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab: a guide to its use in advanced melanoma.
    Lyseng-Williamson KA; Sanford M
    Am J Clin Dermatol; 2012 Oct; 13(5):349-54. PubMed ID: 22849352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma.
    Bernardo SG; Moskalenko M; Pan M; Shah S; Sidhu HK; Sicular S; Harcharik S; Chang R; Friedlander P; Saenger YM
    Melanoma Res; 2013 Feb; 23(1):47-54. PubMed ID: 23262440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
    Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
    Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic correlates in the course of treatment with immunomodulating antibodies.
    Weide B; Di Giacomo AM; Fonsatti E; Zitvogel L
    Semin Oncol; 2015 Jun; 42(3):448-58. PubMed ID: 25965363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy.
    Gajewski TF
    Pigment Cell Melanoma Res; 2010 Oct; 23(5):580-1. PubMed ID: 20609175
    [No Abstract]   [Full Text] [Related]  

  • 13. Ipilimumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1511-21. PubMed ID: 23181437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab: a novel treatment for metastatic melanoma.
    Culver ME; Gatesman ML; Mancl EE; Lowe DK
    Ann Pharmacother; 2011 Apr; 45(4):510-9. PubMed ID: 21505108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
    Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
    [No Abstract]   [Full Text] [Related]  

  • 17. Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.
    Libon F; Arrese JE; Rorive A; Nikkels AF
    Clin Exp Dermatol; 2013 Apr; 38(3):276-9. PubMed ID: 23020081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current advances and perspectives in the treatment of advanced melanoma.
    Livingstone E; Zimmer L; Vaubel J; Schadendorf D
    J Dtsch Dermatol Ges; 2012 May; 10(5):319-25. PubMed ID: 22432863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient.
    Eckert A; Schoeffler A; Dalle S; Phan A; Kiakouama L; Thomas L
    Dermatology; 2009; 218(1):69-70. PubMed ID: 18832811
    [No Abstract]   [Full Text] [Related]  

  • 20. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.